281 related articles for article (PubMed ID: 8221761)
21. Hemodynamic effects of a new angiotensin converting enzyme inhibitor, spirapril, in sodium-loaded and sodium-depleted rabbits.
Hof RP; Hof-Miyashita A; Evenou JP
J Cardiovasc Pharmacol; 1987 Nov; 10(5):599-606. PubMed ID: 2447412
[TBL] [Abstract][Full Text] [Related]
22. Single beat evaluation of circumferential aortic elastin elastic modulus in conscious dogs. Potential application in non-invasive measurements.
Armentano RL; Cabrera Fischer EI; Barra JG; Levenson JA; Simon AC; Pichel RH
Med Prog Technol; 1994; 20(1-2):91-9. PubMed ID: 7968871
[TBL] [Abstract][Full Text] [Related]
23. Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension.
Reams GP; Lau A; Knaus V; Bauer JH
J Clin Pharmacol; 1993 Apr; 33(4):348-53. PubMed ID: 8473550
[TBL] [Abstract][Full Text] [Related]
24. Myocardial effect of converting enzyme inhibition in hypertensive and normotensive rats.
Michel JB; Salzmann JL; Cerol ML; Dussaule JC; Azizi M; Corman B; Camilleri JP; Corvol P
Am J Med; 1988 Mar; 84(3A):12-21. PubMed ID: 2975459
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).
Baum T; Watkins RW; Sybertz EJ; Ahn HS; Nelson S; Coleman W; Tedesco R; Pula KK; Rivelli M; Sabin C
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):230-45. PubMed ID: 2884941
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.
Sybertz EJ; Watkins RW; Ahn HS; Baum T; La Rocca P; Patrick J; Leitz F
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S105-8. PubMed ID: 2485040
[TBL] [Abstract][Full Text] [Related]
28. Increased arterial distensibility induced by the angiotensin-converting enzyme inhibitor, lisinopril, in normotensive rats.
Makki T; Talom RT; Niederhoffer N; Amin F; Tankosic P; Mertès PM; Atkinson J
Br J Pharmacol; 1994 Feb; 111(2):555-60. PubMed ID: 8004398
[TBL] [Abstract][Full Text] [Related]
29. Arterial wall mechanics in conscious dogs. Assessment of viscous, inertial, and elastic moduli to characterize aortic wall behavior.
Armentano RL; Barra JG; Levenson J; Simon A; Pichel RH
Circ Res; 1995 Mar; 76(3):468-78. PubMed ID: 7859392
[TBL] [Abstract][Full Text] [Related]
30. Aortic pulsatile pressure and diameter response to intravenous perfusions of angiotensin, norepinephrine, and epinephrine in conscious dogs.
Cabrera E; Levenson J; Armentano R; Barra J; Pichel R; Simon AC
J Cardiovasc Pharmacol; 1988 Dec; 12(6):643-9. PubMed ID: 2467081
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T
J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729
[TBL] [Abstract][Full Text] [Related]
32. Chronic MK421 fails to modify evolution of hypertension in neonatally coarcted pups.
Bagby SP; Fuchs EF
Hypertension; 1989 Feb; 13(2):91-101. PubMed ID: 2536643
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol improves vasoprotective effects of captopril on aortic remodeling and fibrosis triggered by renovascular hypertension.
Natalin HM; Garcia AF; Ramalho LN; Restini CB
Cardiovasc Pathol; 2016; 25(2):116-9. PubMed ID: 26764145
[TBL] [Abstract][Full Text] [Related]
34. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
Noble S; Sorkin EM
Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
Jackson B; Franze L; Sumithran E; Johnston CI
J Lab Clin Med; 1990 Jan; 115(1):21-7. PubMed ID: 2299253
[TBL] [Abstract][Full Text] [Related]
36. Cough induced activity of spirapril in rats.
Kamei J; Hitosugi H; Kasuya Y
Gen Pharmacol; 1993 Nov; 24(6):1443-5. PubMed ID: 8112517
[TBL] [Abstract][Full Text] [Related]
37. Aortic stiffness and left ventricular mass in a rat model of isolated systolic hypertension.
Tatchum-Talom R; Niederhoffer N; Amin F; Makki T; Tankosic P; Atkinson J
Hypertension; 1995 Dec; 26(6 Pt 1):963-70. PubMed ID: 7490156
[TBL] [Abstract][Full Text] [Related]
38. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril.
van Wijngaarden J; Pinto YM; van Gilst WH; de Graeff PA; de Langen CD; Wesseling H
Cardiovasc Res; 1991 Nov; 25(11):936-42. PubMed ID: 1813122
[TBL] [Abstract][Full Text] [Related]
39. Renal and systemic effects of enalapril in chronic one-kidney hypertension.
Woods RL; Anderson WP; Korner PI
Hypertension; 1986 Feb; 8(2):109-16. PubMed ID: 3002979
[TBL] [Abstract][Full Text] [Related]
40. [Visco-elastic characteristics of the aorta in conscious dogs in a model of experimental calcinosis].
Armentano R; Levenson J; Cabrera E; Pichel R; Simon A
Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1159-62. PubMed ID: 2554835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
